This page contains a Flash digital edition of a book.
6 M. S. Tallman & A. Polliack
19. Fu SM, Winchester RJ, Rai KR, et al. Hairy cell leukemia: 39. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up
proliferation of a cell with phagocytic and B-lymphocyte of patients with hairy cell leukemia after treatment with
properties. Scand J Immunol 1974;3:847–851. cladribine. J Clin Oncol 2003;21:891–896.
20. Haak HL, de Man JC, Hijmans W, et al. Further evidence for 40. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of
the lymphocytic nature of leukaemic reticuloendotheliosis front-line treatment of hairy cell leukemia with 2-chlorodeox-
(hairy-cell leukaemia). Br J Haematol 1974;27:31–38. yadenosine. Haematologica 2004;89:309–313.
21. Jansen J, Hermans J, Remme J, et al. Hairy cell leukaemia. 41. Grever MR, Siaw MF, Jacob WF, et al. The biochemical
Clinical features and effect of splenectomy. Scand J Haematol and clinical consequences of 2
0
-deoxycoformycin in refrac-
1978;21:60–71. tory lymphoproliferative malignancy. Blood 1981;57:406–
22. Mintz U, Golomb HM. Splenectomy as initial therapy in 417.
twenty-six patients with leukemic reticuloendotheliosis (hairy 42. Kraut EH, Bouroncle BA, Grever MR. Low-dose deoxyco-
cell leukemia). Cancer Res 1979;39:2366–2370. formycin in the treatment of hairy cell leukemia. Blood
23. Van Norman AS, Nagorney DM, Martin JK, et al. Splenect- 1986;68:1119–1122.
omy for hairy cell leukemia. A clinical review of 63 patients. 43. Spiers AS, Moore D, Cassileth PA, et al. Remissions in hairy-
Cancer 1986;57:644–648. cell leukemia with pentostatin (2
0
-deoxycoformycin). N Engl J
24. Magee MJ, McKenzie S, Filippa DA, et al. Hairy cell Med 1987;316:825–830.
leukemia. Durability of response to splenectomy in 26 patients 44. Johnston JB, Glazer RI, Pugh L, et al. The treatment of hairy-
and treatment of relapse with androgens in six patients. cell leukaemia with 2
0
-deoxycoformycin. Br J Haematol
Cancer 1985;56:2557–2562. 1986;63:525–534.
25. Quesada JR, Reuben J, Manning JT, et al. aInterferon for 45. Bouroncle BA, Grever MR, Kraut EH. Treatment of hairy cell
induction of remission in hairy-cell leukemia. N Engl J Med leukemia: the Ohio State University experience with deox-
1984;310:15–18. ycoformycin. Leukemia 1987;1:350–354.
26. Quesada JR, Hersh EM, Manning J, et al. Treatment of hairy 46. Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin
cell leukemia with recombinant a-interferon. Blood 1986;68: induces durable remissions in hairy cell leukemia. J Clin Oncol
493–497. 1991;9:243–246.
27. Ratain MJ, Golomb HM, Vardiman JW, et al. Treatment of 47. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-
hairy cell leukemia with recombinant a2 interferon. Blood up of remission duration, mortality, and second malignancies
1985;65:644–648. in hairy cell leukemia patients treated with pentostatin. Blood
28. Golomb HM, Jacobs A, Fefer A, et al. a- 2 interferon therapy 2000;96:2981–2986.
of hairy-cell leukemia: a multicenter study of 64 patients. 48. Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in
J Clin Oncol 1986;4:900–905. the treatment of patients with hairy cell leukemia: results of a
29. Golomb HM, Ratain MJ, Mick R, et al. Interferon treat- Spanish collaborative study of 80 patients. Cancer 2000;88:
ment for hairy cell leukemia: an update on a cohort of 69 352–357.
patients treated from 1983–1986. Leukemia 1992;6: 49. Catovsky D, Matutes E, Talavera JG, et al. Long term results
1177–1180. with 2’deoxycoformycin in hairy cell leukemia. Leuk Lym-
30. Capnist G, Federico M, Chisesi T, et al. Long term results of phoma 1994;14 (Suppl 1) 109–113.
interferon treatment in hairy cell leukemia. Italian Cooperative 50. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy
Group of Hairy Cell Leukemia (ICGHCL). Leuk Lymphoma cell leukemia with purine analogs: a report of 219 patients with
1994;14:457–464. a median follow-up of 12.5 years. Cancer 2005;104:
31. Rai KR, Davey F, Peterson B, et al. Recombinant a-2b- 2442–2448.
interferon in therapy of previously untreated hairy cell 51. Lauria F, Rondelli D, Zinzani PL, et al. Long-lasting
leukemia: long-term follow-up results of study by Cancer complete remission in patients with hairy cell leukemia
and Leukemia Group B. Leukemia 1995;9:1116–1120. treated with 2-CdA: a 5-year survey. Leukemia 1997;11:
32. Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions 629–632.
in hairy-cell leukemia induced by a single infusion of 2- 52. Robak T, Blasinska-Morawiec M, Krykowski E, et al.
chlorodeoxyadenosine. N Engl J Med 1990;322:1117– 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour
1121. intravenous infusion in the treatment of patients with hairy cell
33. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle leukemia. Leuk Lymphoma 1996;22:107–111.
of 2-chlorodeoxyadenosine results in complete remission in 53. Chacko J, Murphy C, Duggan C, et al. Weekly intermittent 2-
the majority of patients with hairy cell leukemia. Blood CdA is less toxic and equally efficacious when compared to
1992;80:2203–2209. continuous infusion in hairy cell leukaemia. Br J Haematol
34. Estey EH, Kurzrock R, Kantarjian HM, et al. Treatment of 1999;105:1145–1146.
hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). 54. Juliusson G, Lenkei R, Tjonnfjord G, et al. Low-dose
Blood 1992;79:882–887. cladribine for symptomatic hairy cell leukaemia. Br J
35. Hoffman MA, Janson D, Rose E, et al. Treatment of hairy-cell Haematol 1995;89:637–639.
leukemia with cladribine: response, toxicity, and long-term 55. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous
follow-up. J Clin Oncol 1997;15:1138–1142. injections of 2-chlorodeoxyadenosine for symptomatic hairy
36. Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of cell leukemia. J Clin Oncol 1995;13:989–995.
hairy cell leukemia after 2-chlorodeoxyadenosine: long-term 56. Saven A, Piro LD. Complete remissions in hairy cell leukemia
follow-up of the Northwestern University experience. Blood with 2-chlorodeoxyadenosine after failure with 2
0
-deoxycofor-
1996;88:1954–1959. mycin. Ann Intern Med 1993;119:278–283.
37. Saven A, Burian C, Koziol JA, et al. Long-term follow-up of 57. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the
patients with hairy cell leukemia after cladribine treatment. treatment of cladribine-failed patients with hairy cell leukemia.
Blood 1998;92:1918–1926. Blood 2003;102:810–813.
38. Jehn U, Bartl R, Dietzfelbinger H, et al. Long-term outcome 58. Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in
of hairy cell leukemia treated with 2-chlorodeoxyadenosine. relapsed or refractory hairy cell leukemia. Blood 2003;102:
Ann Hematol 1999;78:139–144. 3906–3911.
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46
Produced with Yudu - www.yudu.com